With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.17217-57-1,4,4′-Dimethoxy-2,2′-bipyridine,as a common compound, the synthetic route is as follows.
General procedure: [Rh(bpy)2(4,4′-dmobpy)](PF6)3 was prepared as above but using cis-[Rh(bpy)2(OTf)2](OTf) (102 mg, 0.118 mmol) and4,4′-dimethoxy-2,2′-bipyridine (29.3 mg, 0.135 mmol) in 10 mL ethanol and refluxing for 30 min. Yield of analytically pure,off-white product (110 mg, 0.100 mmol), 84percent. Anal. Calcd forC32H28N6RhO4P3F18: C, 34.99; H, 2.57; N, 7.65. Found: C, 35.00; H,2.58; N, 7.55. 1H NMR (d6-DMSO, 400 MHz): d (ppm) aromaticprotons [9.04 (d, J = 8.23 Hz, 4H), 8.67 (d, J = 2.49 Hz, 2H), 8.57 (q,J = 7.95 Hz, 4H), 7.91 (d, J = 5.74 Hz, 2H), 7.84 (t, J = 8.18 Hz, 2H),7.79 (q, J = 5.82 Hz, 4H), 7.57 (d, J = 6.83 Hz, 2H), 7.30 (dd,J = 6.34 Hz, 2H)], 4.08 (s, 6H, OCH3). 13C NMR (d6-DMSO,100 MHz): d (ppm) aromatic carbons [169.8, 155.6, 154.6, 154.5,151.2, 151.0, 150.7, 143.0, 130.4, 126.7, 120.6, 115.6, 113.7], 57.7(OCH3).
17217-57-1, 17217-57-1 4,4′-Dimethoxy-2,2′-bipyridine 2733927, acatalyst-ligand compound, is more and more widely used in various.
Reference£º
Article; Amarante, Daniel; Cherian, Cheryl; Megehee, Elise G.; Inorganica Chimica Acta; vol. 461; (2017); p. 239 – 247;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI